Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01502228 · ClinicalTrials.gov registry record · NA
PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma
A NA study, sponsored by Indiana University.
- Terminated
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT01502228 is a NA study that was terminated before completion, run by Indiana University. The registered enrollment target is 14 participants.
The verdict
NCT01502228, a NA study, was terminated before completion, sponsored by Indiana University.
- TERMINATED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
Given the growing importance of anti-angiogenic therapies in the treatment of metastatic renal carcinoma, it is expected that this trial will establish the preliminary data needed to apply for funding of a larger clinical investigation of the potential role of PET perfusion imaging in management of renal carcinoma, and potentially other cancers.
Interventions
- PROCEDURE Positron Emission Tomography
- DRUG Sunitinib
- DRUG 150-Water
- DRUG 62Cu-ethylglyoxal bis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2011-10 |
| Est. Completion | 2014-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01502228
The ClinicalTrials.gov registry entry for NCT01502228 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Positron Emission Tomography is the first listed.
NCT01502228 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01502228 about?
NCT01502228 is a clinical study titled "PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma". Given the growing importance of anti-angiogenic therapies in the treatment of metastatic renal carcinoma, it is expected that this trial will establish the preliminary data needed to apply for funding of a larger clinical investigation of the potential role of PET perfusion imaging in management of ...
What is the current status of trial NCT01502228?
This trial is currently terminated. It is a NA study. The enrollment target is 14 participants. The study started on 2011-10. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01502228?
The interventions under investigation include: Positron Emission Tomography (PROCEDURE), Sunitinib (DRUG), 150-Water (DRUG), 62Cu-ethylglyoxal bis (DRUG).
Who is sponsoring clinical trial NCT01502228?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.